지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한소아소화기영양학회 Pediatric Gastroenterology, Hepatology & Nutrition Pediatric Gastroenterology, Hepatology & Nutrition 제20권 제4호
- 발행연도
- 2017.1
- 수록면
- 236 - 243 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: Studies on the efficacy of infliximab (IFX) in a large population of pediatric patients with Crohn’s disease (CD) are limited, and prognostic factors are not well-known. The aim of this study was to evaluate outcomes of IFX in pediatric patients with CD and to identify factors associated with poor prognosis.Methods: We retrospectively analyzed medical data of 594 pediatric patients with CD between 1987 and 2013 in a tertiary center. Of these, 156 children treated with IFX were enrolled and were followed up for at least a year with intact data. Outcomes of induction and maintenance, classified as failure or clinical response, were evaluated onthe tenth and 54th week of IFX therapy.Results: We treated 156 pediatric patients with CD with IFX, and the median duration of IFX therapy was 47 months. For IFX induction therapy, 134 (85.9%) patients experienced clinical response on the 10th week. Among the 134 patients who showed response to induction, 111 (82.8%) patients maintained the clinical response on the 54th week. In multivariate analysis, low hematocrit (p=0.046) at the time of IFX initiation was associated with the failure of IFX induction. For IFX maintenance therapy, longer duration from the initial diagnosis to IFX therapy (p=0.017) was asso-ciated with maintenance failure on the 54th week.Conclusion: We have shown the acceptable outcomes of IFX in a large cohort of pediatric CD patients in Korea. Hematocrit and early introduction of IFX may be prognostic factors for the outcomes of IFX.
목차
등록된 정보가 없습니다.
참고문헌 (30)
참고문헌 신청
Ruffolo C / 2010 / Infliximab, azathioprine, or combination therapy for Crohn's disease / N Engl J Med 363:1086~1087
Koutroubakis IE / 2015 / Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease / Clin Gastroenterol Hepatol 13:1760~1766
Rieder F / 2014 / Hemoglobin and hematocrit levels in the prediction of complicated Crohn's disease behavior--a cohort study / PLoS One 9:e104706
Koutroubakis IE / 2015 / The influence of anti-tumor necrosis factor agents on hemoglobin levels of patients with inflammatory bowel disease / Inflamm Bowel Dis 21:1587~1593
Bergamaschi G / 2010 / Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment / Haematologica 95:199~205
Koutroubakis IE / 2015 / Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease / Clin Gastroenterol Hepatol 13:1760~1766
Rieder F / 2014 / Hemoglobin and hematocrit levels in the prediction of complicated Crohn's disease behavior--a cohort study / PLoS One 9:e104706
Koutroubakis IE / 2015 / The influence of anti-tumor necrosis factor agents on hemoglobin levels of patients with inflammatory bowel disease / Inflamm Bowel Dis 21:1587~1593
Bergamaschi G / 2010 / Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment / Haematologica 95:199~205
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan
Pediatric Gastroenterology, Hepatology & Nutrition
2021 .01
-
Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn’s Disease: A Systematic Review of Real-World Evidence Studies
Pediatric Gastroenterology, Hepatology & Nutrition
2020 .01
-
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Intestinal research
2021 .10
-
Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
Gut and Liver
2017 .01
-
Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
Gut and Liver
2019 .01
-
Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
Gut and Liver
2021 .01
-
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Gut and Liver
2021 .01
-
High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
Intestinal research
2018 .01
-
Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
Intestinal research
2022 .01
-
Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab
Journal of Yeungnam Medical Science
2021 .01
-
Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
Yonsei Medical Journal
2020 .01
-
Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy
Yonsei Medical Journal
2021 .01
-
Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
Gut and Liver
2016 .01
-
Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease
Gut and Liver
2024 .05
-
Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
Intestinal research
2021 .01
-
크론병에서 인플릭시맵 투약 후 발생한 전신홍반루푸스 1예
대한내과학회지
2019 .06
-
Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
Journal of Yeungnam Medical Science
2021 .01
-
Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn’s Disease: A Nationwide, Multicenter Study
Yonsei Medical Journal
2016 .01
-
Anti-Saccharomyces cerevisiae Antibody in Pediatric Crohn’s Disease Patients without Mucosal Healing Is a Useful Marker of Mucosal Damage
Gut and Liver
2021 .09
-
Dietary Therapies for Management of Crohn’s Disease
대한외과학회 학술대회 초록집
2022 .11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0